Announcement of an Exempt Purchase

Curascript provides specialty pharmaceutical products for UI Health patients. These products include: flolan, letaris, remodulin, tracleer and veletri. Most recently, the hospital has decided to start providing CART�therapy using the product Kymriah to its patient population. This therapy is for patients who have failed previous cancer treatment and is considered a last option.

This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical services necessary for the delivery of care and treatment at medical, dental, or veterinary teaching facilities utilized by SIU or U of I (30 ILCS 500 / 1-13(b-5)) Curascript is the specialty pharmaceutical vendor that is able to distribute Kymriah to hospitals wishing to provide this therapy to its patient population. Novartis (pharmaceutical company that supplies Kymriah) has put in place a limited distribution system for this drug.